DGAP-News

Vita 34 AG: Positive Development of Business in the First Nine Months of 2014 - Seite 2

underscores the profitability of our business activities. In addition, Vita
34 has strengthened its market position in the reporting period. To date,
the parents of nearly 108,000 children have had stem cell preparations
stored at Vita 34. Thus, Vita 34 is undisputedly the largest and
market-leading private stem cell bank in the German-speaking countries, and
numbers among the top three larges umbilical cord blood banks in Europe. We
want to further expand this market position", said Dr. Gerth.

The main basis for the positive development of the company was a consistent
continuation of the growth strategy. The focus lay primarily in obtaining
collection permits for umbilical cord tissue for more than 700 German
partner clinics. As of the end of the reporting period, Vita 34 had
received approval from a majority of the regionally responsible
authorities. Correspondingly, Vita 34 entered into agreements in Germany
and in Austria with additional clinics concerning the collection of
umbilical cord tissue, which has already had its first positive effects on
the number of new storages. The introduction of umbilical cord tissue was
advanced with partners in further European countries. Vita 34 expects
significant positive effects on group revenues and profits in the future
from the storage of umbilical cord tissue.

On account of the delayed issuance during the year of official approvals
for the collection of umbilical cord tissue, the Management Board estimates
the operating profit (EBITDA) for the entire year 2014 will be below
previous expectations, however, that it will be higher than the prior
year's level. With the further issuance of official permits for the
collection and storage of umbilical cord tissue, an increasing positive
trend with regard to the development of revenues and profits is to be
expected for 2015.

The complete 9-month report 2014 is available for download immediately on
the website at www.vita34group.com in the "Investor Relations" section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and cord tissue. The basis
for its successful work is an outstanding position in the technological
segment of cryo-preservation. Here, cells and tissue are preserved alive at
some -190ºC for long periods of time, and can be used if needed in the
context of medical treatment. Parents of nearly 108,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit at Vita 34.



---------------------------------------------------------------------

23.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
292914 23.10.2014